 |
| |
|
| |
February 8, 2010 (Issue 1331) Subscriber Download: Full Text or PDF  | |
|
|
| Asenapine (Saphris - Schering-Plough), a dibenzo-oxepino pyrrole, has been approved by the FDA in a sublingual tablet formulation for acute treatment of schizophrenia and manic or mixed episodes associated with bipolar disorder. It is the sixth second-generation antipsychotic approved by the FDA for use in bipolar disorder.1 English Canadian version: Full Text or PDF | |
|
| The FDA has approved the marketing of a 10% topical gel formulation of the muscarinic receptor antagonist oxybutynin chloride (Gelnique - Watson) for treatment of overactive bladder. Oxybutynin is also available for this indication as oral tablets, an oral syrup and a transdermal patch. English Canadian version: Full Text or PDF | |
|
| Bepotastine besilate 1.5% ophthalmic solution (Bepreve - ISTA Pharmaceuticals), an H1-antihistamine, has been approved by the FDA for topical treatment of itching associated with allergic conjunctivitis in patients ≥2 years old. Bepotastine was first developed in an oral systemic formulation and has been used as such for treatment of allergic rhinitis in Japan. English Canadian version: Full Text or PDF | |
| |
|
| |
|
|
| Fourteen states in the US - Alaska, California, Colorado, Hawaii, Maine, Michigan, Montana, Nevada, New Jersey, New Mexico, Oregon, Rhode Island, Vermont and Washington - now permit, or soon will permit, some medical use of marijuana (Cannabis sativa). In some states, licensed facilities dispense botanical cannabis by prescription. In others, limited self-cultivation is permitted for medical use. English Canadian version: Full Text or PDF | |
|
| Once thought to be a beneficial response to critical illness, hyperglycemia is now recognized as independently associated with death and other adverse outcomes in various groups of critically ill patients. Whether normalization of blood glucose by insulin infusion is beneficial in such patients has been a subject of debate in the critical care community. Some new guidelines have been published. English Canadian version: Full Text or PDF | |
|
| The FDA has approved the use of ustekinumab (Stelara - Centocor Ortho Biotech), an interleukin antagonist given by subcutaneous (SC) injection for treatment of adults with moderate to severe plaque psoriasis. It is the first agent in its class for this indication; the other biologic agents for psoriasis are Tcell or tumor necrosis factor (TNF) inhibitors. English Canadian version: Full Text or PDF | |
| |
|
| |
| January 11, 2010 (Issue 1329) Subscriber Download: Full Text or PDF | |
|
|
| Telavancin (Vibativ - Astellas and Theravance), a lipoglycopeptide derivative of vancomycin (Vancocin, and others), has received FDA approval for treatment of complicated skin and skin structure infections caused by susceptible gram-positive bacteria in adults. English Canadian version: Full Text or PDF | |
|
| The FDA has approved Twynsta (Boehringer Ingelheim), a fixed-dose combination of the calcium-channel blocker (CCB) amlodipine and the angiotensin receptor blocker (ARB) telmisartan, for treatment of hypertension. English Canadian version: Full Text or PDF | |
|
| An intraveneous (IV) formulation of ibuprofen (Caldolor - Cumberland) was recently approved by the FDA for use in adults. It can be administered alone for treatment of mild to moderate pain or as an adjunct to opioid analgesics for moderate to severe pain. It is also approved for reduction of fever. English Canadian version: Full Text or PDF | |
| |
|
| |
|
|
 FREE
to everyone |
 FREE
to subscribers
Issue is available online to The Medical Letter
subscribers signed up for online privileges. |
 Issue is free to institutional users. |
 $12.00
Non-subscribers may order copies of this
issue of The Medical Letter and receive
by postal mail or electronic download. |
 $10.00
Non-subscribers may purchase online by credit
card on our secure server and download this The
Medical Letter article. |
|
 |
 FREE
to everyone |
 FREE
to subscribers
Issue is available online to Treatment Guidelines
subscribers signed up for online privileges. |
 Issue is free to institutional users. |
 $12.00
Non-subscribers may order copies of this
issue of Treatment Guidelines and receive
by postal mail or electronic download. |
|
|
|
| WANT
TO SUBSCRIBE? |
| Subscribing
online to The Medical Letter or Treatment
Guidelines gives you the following privileges: |
| |
 |
Access to the current issue of The Medical Letter
or Treatment Guidelines (two separate subscriptions)
on the day it is published. |
| |
|
Access
to all articles published by The Medical Letter
since 1988 or to Treatment Guidelines since its
inception (September 2002). |
| |
|
As
a subscriber to The Medical Letter or Treatment
Guidelines, you will also receive your copy of the
current issue by postal mail. |
| |
|
 |
Individual Subscriptions - Individual print and online access, including access to a limited section of the searchable archives. Shared access not allowed. |
|
Individual Librarian Subscriptions - Print and online access for the head librarian only. It allows the librarian to conduct searches and provide data. Shared access not allowed. |
|
Group Site License - Preview Site License. Print and online access for multiple users at multiple locations including access to the entire searchable archives. Please e-mail us for further information regarding The Medical Letter's pricing platform for site licenses. |
|
| |
 |
|
|
| |
| |
